Last kr133.00 SEK
Change Today +3.00 / 2.31%
Volume 17.9K
VITR On Other Exchanges
Symbol
Exchange
Stockholm
OTC US
Frankfurt
As of 11:30 AM 09/19/14 All times are local (Market data is delayed by at least 15 minutes).

vitrolife ab (VITR) Snapshot

Open
kr130.00
Previous Close
kr130.00
Day High
kr134.00
Day Low
kr130.00
52 Week High
09/19/14 - kr134.00
52 Week Low
09/30/13 - kr69.75
Market Cap
2.6B
Average Volume 10 Days
24.1K
EPS TTM
kr3.90
Shares Outstanding
19.8M
EX-Date
05/6/14
P/E TM
34.1x
Dividend
kr1.00
Dividend Yield
0.75%
Current Stock Chart for VITROLIFE AB (VITR)

Related News

No related news articles were found.

vitrolife ab (VITR) Related Businessweek News

No Related Businessweek News Found

vitrolife ab (VITR) Details

Vitrolife AB (publ), a medical device company, develops, produces, and markets products for assisted reproduction worldwide. The company offers fertility products, such as nutrient solutions; paraffin oil; additional media for in vitro fertilisation (IVF) procedures; vitrification products; G-Series media products; various sterile disposable instruments, including needles and pipettes used in IVF treatment; embryo monitoring solutions; micromanipulation solutions; sperm processing solutions; slow freezing products; and labware products comprising plastic dishes and test tubes required in an IVF lab. It also provides cell therapy services to researchers and cell therapy companies. The company was formerly known as Scandinavian IVF Science and changed its name to Vitrolife AB (publ) in 1998. Vitrolife AB (publ) was founded in 1981 and is headquartered in Göteborg, Sweden.

240 Employees
Last Reported Date: 07/11/14
Founded in 1981

vitrolife ab (VITR) Top Compensated Officers

Chief Executive Officer
Total Annual Compensation: kr3.7M
Compensation as of Fiscal Year 2013.

vitrolife ab (VITR) Key Developments

Vitrolife AB (publ) Reports Consolidated and Parent Earnings Results for the Second Quarter and Six Months Ended June 30, 2014

Vitrolife AB (publ) reported consolidated and parent earnings results for the second quarter and six months ended June 30, 2014. For the six months, on consolidated basis, net sales were SEK 248.5 million against SEK 220.6 million last year. Operating income was SEK 63.5 million against SEK 35.6 million last year. Income after financial items was SEK 61.2 million against SEK 34.7 million last year. Net income attributable to parent company's shareholders was SEK 45.2 million against SEK 24 million last year. Earnings per share were SEK 2.28 against SEK 1.21 last year. Return on equity was 24.2% against 11.0% last year. Cash flow from operating activities per share was SEK 2.66 against SEK 1.89 last year. Cash flow from operating activities was SEK 52.8 million against SEK 37.5 million last year. Operating income before depreciation and amortization (EBITDA) was SEK 74 million against SEK 46 million last year. For the second quarter, on consolidated basis, net sales were SEK 129.4 million against SEK 116 million last year. Operating income was SEK 33.6 million against SEK 18.6 million last year. Income after financial items was SEK 31.6 million against SEK 17.5 million last year. Net income attributable to parent company's shareholders was SEK 23.0 million against SEK 12.1 million last year. Earnings per share were SEK 1.16 against SEK 0.61 last year. Return on equity was 24.2% against 11.0% last year. Cash flow from operating activities per share was SEK 1.43 against SEK 0.9 last year. Cash flow from operating activities was SEK 28.4 million against SEK 17.9 million last year. Operating income before depreciation and amortization (EBITDA) was SEK 38 million against SEK 24 million last year. For the six months, on parent basis, operating loss was SEK 1.8 million against SEK 2.8 million last year. Loss after financial items was SEK 2.9 million against SEK 3.3 million last year. Net loss was SEK 2.3 million against SEK 2.6 million last year. For the second quarter, on parent basis, operating loss was SEK 2.0 million against SEK 1.3 million last year. Loss after financial items was SEK 2.8 million against SEK 3.8 million last year. Net loss was SEK 2.2 million against SEK 2.9 million last year.

Vitrolife AB (publ) Approves Dividend for the Financial Year 2013

Vitrolife AB (publ) at its AGM held on May 5, 2014 approved dividend of SEK 1.00 per share for the financial year 2013. May 8, 2014 was adopted as the record day.

Vitrolife AB (Publ) Elects Deloitte AB as Auditor

The annual general meeting of Vitrolife AB (publ) was held on May 5, 2014. At the meeting the shareholders will consider election of Deloitte AB, with authorized public accountant Jan Nilsson as head auditor, and authorized public accountant Fredrik Jonsson as auditors for a term of three years.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
VITR:SS kr133.00 SEK +3.00

VITR Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Bionet Corp 43.30 TWD +0.70
Cryo-Cell International Inc $3.25 USD -0.012
CryoLife Inc $10.21 USD +0.07
Esperite €1.70 EUR +0.085
Osiris Therapeutics Inc $13.46 USD +0.31
View Industry Companies
 

Industry Analysis

VITR

Industry Average

Valuation VITR Industry Range
Price/Earnings 31.8x
Price/Sales 5.1x
Price/Book 7.2x
Price/Cash Flow 31.8x
TEV/Sales 4.9x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact VITROLIFE AB, please visit www.vitrolife.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.